Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA.
Int J Gynaecol Obstet. 2010 Jun;109(3):216-8. doi: 10.1016/j.ijgo.2010.01.005. Epub 2010 Feb 21.
To assess the knowledge and practice of health professionals in Manila, Philippines, regarding methods used for uterine evacuation in post-abortion care (PAC), including the use of misoprostol.
A purposive sample of physicians providing PAC services completed questionnaires anonymously about PAC practices.
Among 45 survey respondents, the primary methods used for first-trimester uterine evacuation in PAC included sharp curettage (n=45, 100%) and manual vacuum aspiration (MVA; n=38, 84.4%), which was consistent with their preferences. Misoprostol was prescribed for first-trimester post-abortion uterine evacuation by 55.6% (n=25) of respondents; dosing regimens ranged from 50 to 200 microg as a single dose or repeated every 4-24 hours. Of the respondents, 91.1% (n=41) prescribed misoprostol for obstetric indications, including labor induction and postpartum hemorrhage.
Most respondents used sharp curettage and MVA for first-trimester post-abortion uterine evacuation, and did not express a clear preference for either method. Despite the unregistered status of misoprostol, it was used in obstetrics and PAC by a majority of study respondents. The doses of misoprostol used for post-abortion uterine evacuation are lower than those recommended by evidence-based studies. The results indicate the need to disseminate evidence-based information about safe and effective use of MVA and misoprostol for PAC to physicians in Manila, Philippines.
评估菲律宾马尼拉的卫生专业人员在流产后护理 (PAC) 中使用的子宫排空方法（包括米索前列醇的使用）方面的知识和实践。
对提供 PAC 服务的医生进行了一项有目的的抽样调查，他们匿名填写了关于 PAC 实践的问卷。
在 45 名调查受访者中，PAC 中用于早期妊娠子宫排空的主要方法包括刮宫术（n=45，100%）和手动真空抽吸术（MVA；n=38，84.4%），这与他们的偏好一致。55.6%（n=25）的受访者开米索前列醇用于早期妊娠流产后子宫排空；剂量方案范围从 50 到 200 微克，单次剂量或每 4-24 小时重复一次。在受访者中，91.1%（n=41）开米索前列醇用于产科适应症，包括引产和产后出血。
大多数受访者使用刮宫术和 MVA 进行早期妊娠流产后子宫排空，对这两种方法均无明显偏好。尽管米索前列醇未注册，但大多数研究受访者在产科和 PAC 中使用。用于流产后子宫排空的米索前列醇剂量低于基于证据的研究推荐的剂量。结果表明，需要向菲律宾马尼拉的医生传播有关 MVA 和米索前列醇在 PAC 中安全有效使用的基于证据的信息。
